ECElena Chamorro Chirinos

Elena Chamorro Chirinos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Chamorro Chirinos has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determining the Impact of Exogenous Factors in Acute Respiratory Infections Using a Mathematical Epidemiological Model—Case Study of COVID-19 in a Peruvian Hospital

    by Pedro I. Pesantes-Grados, Emma Cambillo-Moyano, Erasmo H. Colona-Vallejos, Libertad Alzamora-Gonzales, Dina Torres Gonzales, Giannina Tineo Pozo, Elena Chamorro Chirinos, Cynthia Lorenzo Quito, Elias E. Aguirre-Siancas, Eliberto Ruiz-Ramirez, et al.

    In this study, we develop and analyze an extended SEIR-type compartmental model that incorporates vaccination and treatment to describe the dynamics of acute respiratory infection transmission. The model subdivides the infectious population into several symptomatic stages and an asymptomatic class, which allows the evaluation of control strategies across different levels of infection severity. The basic reproduction number R0 is analytically derived, and its sensitivity to vaccination and treatment rates is examined to assess the impact of public health interventions on epidemic control. Numerical simulations demonstrate that the joint implementation of vaccination and treatment can markedly reduce disease prevalence and lead to infection elimination when R0<1. The results emphasize the critical role of parameter interactions in determining disease persistence and show that combining both interventions produces stronger epidemiological effects than either one alone. Machine learning techniques, specifically Support Vector Machines (SVMs), are employed to classify epidemiological outcomes and support parameter estimation. The biological markers evaluated were not effective discriminants of infection status, underscoring the importance of integrating mechanistic modeling with data-driven approaches. This combined framework enhances the understanding of epidemic dynamics and improves the predictive capacity for decision-making in public health.

  • Open Access

    CD4+/CD8+ lymphocyte ratio as a biomarker of morbidity and severity in patients with moderate and severe COVID-19

    by D. Torres-Gonzales, E. Colona-Vallejos, L. Alzamora-Gonzales, G. Tineo Pozo, E. Chamorro Chirinos, C. Lorenzo Quito, M. Aliaga Zamudio, E. Cambillo Moyano, E. E. Aguirre-Siancas, E. Ruiz Ramirez

    The assessment of lymphocyte populations allows the monitoring, follow-up and treatment of patients with various infectious diseases. Acute respiratory syndrome caused by coronavirus (SARS-CoV-2), can lead to a decrease in circulating lymphocytes and cause disease progression and severity. We evaluated the association of CD4+/CD8+ T lymphocyte with COVID-19 disease severity in moderate and severe patients. 136 patients with COVID-19 from the moderate group (MG) and severe group (SG) were compared with a healthy group or control group (CG). CD3+, CD4+ and CD8+ T lymphocytes were quantified by flow cytometry and correlated to CD4+/CD8+ with sex, age, markers of inflammation (ferritin, C-reactive protein and D-dimer), lung damage and oxygen saturation. CD4+ and CD8+ T lymphocytes were significantly decreased in MG and SG (p<0.0001). The CD4+/CD8+ ratio showed association in MG with age (r=0.31; p=0.056), with lung damage (r=0.4; p=0.03) and in SG with total proteins (r=0.59; p=0.04) and D-dimer (r=0.57; p=0.03). The CD4+/CD8+ ratio is associated with disease severity, significantly affecting the cellular immune response.

  • Open Access

    Éxito de los antivirales de acción Directa para hepatitis C en pacientes VIH-positivos de un hospital terciario, Lima, Perú

    by Jaime A. Collins, Elena R. Chamorro, Raúl A. Castillo, Grupo de estudio de SIDA Hospital Nacional EsSalud Guillermo Almenara Irigoyen

    Objective: to present the results of the virological response in the medium term, based on the success of therapy with direct-acting antivirals (DAA) for chronic hepatitis C in the first series of HIVpositive patients reported at national level. Methods: longitudinal and prospective study from a series of HIV-positive patients with chronic hepatitis C treated with DAA and with evidence of success three years earlier. This was carried out between June and August 2023, at the Infectious Diseases Department of the EsSalud Guillermo Almenara Irigoyen National Hospital, Lima, Peru. The virological response of hepatitis C virus (HCV) was evaluated in terms of viral load. Results: of the nine patients included in the study, two were women (22%). One patient received sofosbuvir and daclatasvirseparately (SOF + DCV), while the remaining eight received sofosbuvir and velpatasvir in fixed-dose combination (SOF/ VEL). All patients maintained suppressed HIV viral load while, at 169 weeks, HCV viral load remained undetectable, except in one patient who presented an elevated viral load, which wasconsidered as a case of recurrent hepatitis C (11%). Conclusion: the results of the present series at 169 weeks are a sample of the benefits that can be obtained with DAAs for hepatitis C in the potential eradication of the disease. Objetivo: presentar los resultados de la respuesta virológica a mediano plazo, a partir del éxito en la terapia con antivirales de acción directa (AAD) para hepatitis C crónica en la primera serie de pacientes VIH-positivos reportada a nivel nacional. Material y métodos: estudio longitudinal y prospectivo a partir de una serie de pacientes VIH-positivos con hepatitis C crónica tratados con AAD y con evidencia de éxito tres años antes. Esto se llevó a cabo entre junio yagosto de 2023, en el Servicio de Infectología del Hospital Nacional EsSalud Guillermo Almenara Irigoyen, Lima, Perú. La respuesta virológica del virus de hepatitis C (VHC) se evaluó en términos de carga viral. Resultados: de los nueve pacientes incluidos en el estudio, dos eran mujeres (22 %). Un paciente recibió sofosbuvir y daclatasvir por separado (SOF + DCV), mientras que los ocho restantes sofosbuvir y velpatasvir en combinación de dosis fija (SOF/VEL). Todoslos pacientes mantuvieron suprimida la carga viral del VIH en tanto que, a las 169 semanas, la del VHC se mantuvo indetectable, excepto en un paciente que presentó una carga viral elevada, lo que se consideró como un caso de hepatitis C recurrente (11 %). Conclusión: los resultados de la presente serie a 169 semanas son una muestra de los beneficios que se pueden obtener con los AAD para hepatitis C en la potencial erradicación de la enfermedad.

  • Open Access

    Clinical validation of RCSMS: a rapid and sensitive CRISPR-Cas12a test for the molecular detection of SARS-CoV-2 from saliva

    by Joaquín Abugattás Núñez del Prado, Angélica Quintana Reyes, Juan Blume La Torre, Renzo Gutiérrez Loli, Alejandro Pinzón Olejua, Elena Rocío Chamorro Chirinos, Félix Antonio Loza Mauricio, Jorge L. Maguiña, Julio Leon, Piere Rodríguez Aliaga, et al.

    Early detection of SARS-CoV-2 using molecular techniques is paramount to the fight against COVID-19. Due to its high sensitivity and specificity, RT-qPCR is the “gold standard” method for this purpose. However, its technical requirements, processing time and elevated costs hamper its use towards massive and timely molecular testing for COVID-19 in rural and socioeconomically deprived areas of Latin America. The advent and rapid evolution of CRISPR-Cas technology has boosted the development of new pathogen detection methodologies. Recently, DETECTR -a combination of isothermal RT-LAMP amplification and Cas12a-mediated enzymatic detection-has been successfully validated in the Netherlands and the USA as a rapid and low-cost alternative to RT-qPCR for the detection of SARS-CoV-2 from nasopharyngeal swabs. Here, we evaluated the performance of RCSMS, a locally adapted variant of DETECTR, to ascertain the presence of SARS-CoV-2 in saliva samples from 276 patients in two hospitals in Lima, Perú (current status over a total of 350 samples ). We show that a low-cost thermochemical treatment with TCEP/EDTA is sufficient to inactivate viral particles and cellular nucleases in saliva, eliminating the need to extract viral RNA with commercial kits, as well as the cumbersome nasopharyngeal swab procedure and the requirement of biosafety level 2 laboratories for molecular analyses. Our clinical validation shows that RCSMS detects up to 5 viral copies per reaction in 40 min, with sensitivity and specificity of 93.8% and 99.0% in the field, respectively, relative to RT-qPCR. Since CRISPR-Cas biosensors can be easily reprogrammed by using different guide RNA molecules, RCSMS has the potential to be quickly adapted for the detection of new SARS-CoV-2 variants. Notably, estimation of its negative and positive predictive values suggests that RCSMS can be confidently deployed in both high and low prevalence settings. Furthermore, our field study validates the use of lateral flow strips to easily visualize the presence of SARS-CoV-2, which paves the way to deploy RCSMS as a “point of care” test in environments with limited access to state-of-the-art diagnostic laboratories. In sum, RCSMS is a fast, efficient and inexpensive alternative to RT-qPCR for expanding COVID-19 testing capacity in low- and middle-income countries.